Factors Affecting Carisoprodol Metabolism in Pain Patients Using Urinary Excretion Data
Authors:
Open Access
- 31 January 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 38 (3) , 122-128
Abstract
Carisoprodol is a skeletal muscle relaxant prescribed to treat pain. Carisoprodol is metabolized to meprobamate, an active metabolite with anxiolytic effects, by the genetically polymorphic CYP2C19 enzyme. Concomitant use of CYP2C19 substrates or inhibitors may alter carisoprodol metabolism, with therapeutic and/or toxic implications for effectively treating patients with pain. This was a retrospective analysis of urinary excretion data collected from patients with pain from March 2008 to May 2011. Carisoprodol and meprobamate urine concentrations were measured by liquid chromatography–tandem mass spectrometry, and the metabolic ratio (MR) of meprobamate to carisoprodol concentrations was determined in 14,965 subjects. The MR geometric mean and 95% confidence interval (95% CI) of the young group (105, 95% CI = 99.1–113) were ∼47.4% higher than the middle-aged group (71.9, 95% CI = 70–73.8) and nearly two times higher than the elderly group (54.4, 95% CI = 51.3–57.6). Females had a 20.7% higher MR compared with males. No significant change in the MR was observed with overall CYP2C19 inhibitor or substrate use. However, evaluation of individual inhibitors showed co-administration with esomeprazole or fluoxetine was associated with a 31.8 and 24.6% reduction in MR, respectively, compared with controls (P < 0.05). Omeprazole did not significantly affect the MR. Patient-specific factors such as age, sex and co-medications may be important considerations for effective carisoprodol therapy.Keywords
This publication has 25 references indexed in Scilit:
- Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trialAmerican Heart Journal, 2011
- The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with ClopidogrelDrug Metabolism and Disposition, 2011
- Influences of different proton pump inhibitors on the anti‐platelet function of clopidogrel in relation to CYP2C19 genotypesBritish Journal of Clinical Pharmacology, 2010
- Age and sex dependent changes in liver gene expression during the life cycle of the ratBMC Genomics, 2010
- Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo StudiesThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and ClopidogrelThe Journal of Clinical Pharmacology, 2008
- Carisoprodol use and abuse in Norway. A pharmacoepidemiological studyBritish Journal of Clinical Pharmacology, 2007
- Urine drug testing in pain medicineJournal of Pain and Symptom Management, 2004
- Formation of meprobamate from carisoprodol is catalysed byCYP2C19Pharmacogenetics, 1996
- Carisoprodol Elimination in HumansTherapeutic Drug Monitoring, 1994